



# **Hepatic Dysfunction In Renal Transplant Recipients**

## **Thesis**

Submitted By  
**Ahmed Moustafa Taha Mohamed**  
(M.B.B.Ch, Dip.)

In partial fulfillment of Master Degree in  
**Nephrology**

### ***SUPERVISED BY***

**Prof. Dr. Essam Mohamed Khedr**

*Prof. of Internal medicine and nephrology  
Ain Shams faculty of medicine*

**Prof. Dr. Ahmed Aziz Abd El Nabi**

*Prof. of Internal medicine and nephrology  
Ain Shams faculty of medicine*

**Dr. Sahar Mahmoud Shawky**

*Assist. Prof. of Internal medicine and nephrology  
Ain Shams faculty of medicine*

**2012**

# **Acknowledgment**

To **GOD**, I owe all thanks and gratitude, for giving me help and power to complete this work.

Special thanks to **Prof. Dr. Essam Mohamed Khedr**, professor of internal medicine and nephrology, faculty of medicine, Ain Shams University, for his support, guidance, positive attitude and assurance, working with him caused me a real pleasure.

I'm deeply thankful and grateful to **Prof. Dr. Ahmed Aziz Abd El Nabi**, professor of internal medicine and nephrology, faculty of medicine, Ain Shams University, for his patience, continuous support, and help, invaluable expert and scientific guidance.

I'm so grateful and thankful to **Dr. Sahar Mahmoud Shawky** assistant professor of internal medicine and nephrology, faculty of medicine, Ain Shams University, she offered me an unrelenting support, beside her friendly kind attitude and endless patience and guidance, which add to me a lot both in science and character, without her support this work would have never been realized.

To my parents and parents-in-law, who contained me with love, kindness.

At last, but not least, I would like to thank my dear wife for her love, courage, patience, and constant support.

# Contents

Title	Page
Abbreviations .....	III
Tables.....	V
Figures.....	VIII
Introduction & Aim of work .....	1
Review of literature .....	
• Renal transplantation.....	7
• Liver anatomy.....	21
• Hepatic dysfunction after transplantation.	34
• Prognostic Score Models.....	161
Patients and methods .....	171
Results .....	177
Discussion .....	211
Summary and conclusion .....	230
References.....	234
Arabic summary .....	284

## Abbreviations Table

AIDS	Acquired immune deficiency syndrome
ALG	Antilymphocyte globulin
ALT	Alanine aminotransferases
AST	Aspartate aminotransferase
ATG	Anti thymocyte globulin
ATP	Adenosine triphosphate
ATT	Antituberculous treatment
AZT	Azathioprine
BPAR	Biopsy Proven Acute Rejection
CAN	Chronic allograft nephropathy
CFT	Complement Fixation Test
CMV	Cytomegalovirus
CsA	Cyclosporine A
CT	Computed tomography
CTP	Child-Turcotte-Pugh
CTP	Child-Turcotte-Pugh score
DEAFF	Detection of early antigen fluorescent foci
DM	Diabetes mellitus
EBV	Epstein-Barr virus
ELISA	Enzyme-linked immunosorbent assay
ETVR	End of treatment virological response
FK-506	Tacrolimus
G-CSF	Granulocyte colony-stimulating factor
GFR	Glomerular filtration rate
GFR	Glomerular Filtration Rate
GIT	Gastrointestinal tract
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C Virus
HEL	Human embryo lung
HHV	Human Herpes Virus

HIV	Human immune deficiency virus
HSV	Herpes simplex virus
IFT	Indirect immunofluorescence test
IgG	Immunoglobulin G
IgM	Immunoglobulin M
JASN	Journal of American Society of Nephrology
LD	Lactate dehydrogenase
LFTs	Liver Function Tests
MELD	Model for End-Stage Liver Disease
MMF	Mycophenolate mofetil
NAFLD	nonalcoholic fatty liver disease
NASH	nonalcoholic steatohepatitis
NODAT	New Onset Diabetes After Transplantation
NRH	Nodular regenerative hyperplasia
PCR	Polymerase chain reaction.
PTDM	Post transplant Diabetes Mellitus
RIA	Radioimmunoassay
SGOT	Serum glutamic oxaloacetic transaminase
SGPT	Serum glutamic pyruvic transaminase
SVR	Sustained virological response
TH0	T Helper 0 cells
TH2	T Helper 2 cells
UNOS	United Network for Organ Sharing
VZV	Varicella zoster Virus

## Tables

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
Table .١	Metabolism related to the zonal location of the hepatocyte	<b>28</b>
Table .٢	Tests for Hepatitis C Virus	<b>50</b>
Table .٣	Medications That Stimulate or Inhibit the Cytochrome P-450	<b>142</b>
Table .٤	Child-Turcotte-Pugh score	<b>162</b>
Table .٥	Interpretation of Child-Turcotte-Pugh score	<b>163</b>
Table .٦	Number of patients in each group according to the hepatic dysfunction criteria.	<b>177</b>
Table .٧	Shows the demographic data of the recipients in two groups	<b>178</b>
Table .٨	Shows some risk factors pre transplantation to the recipients in two groups	<b>179</b>
Table .٩	Shows the demographic data of the donors in two groups.	<b>180</b>
Table .١٠	Comparison of the etiology of renal failure among the two groups	<b>180</b>
Table .١١	Mean serum alanine transferase level (IU/liter) at comparable time points during study	<b>182</b>
Table .١٢	Mean serum Aspartate transaminase level (IU/liter) at comparable time points during study	<b>183</b>
Table .١٣	Mean serum bilirubin levels (mg / dl ) at comparable time points during study	<b>184</b>
Table .١٤	Mean serum albumin levels (mg / dl ) at comparable time points during study	<b>185</b>
Table .١٥	Mean hemoglobin values (gm /dl)	<b>186</b>

	at comparable time points during the study	
Table .١٦	Mean blood white blood cells (WBCs) values (103 /mm3 ) at comparable time points during the study	<b>187</b>
Table .١٧	Mean blood platelets values (103 /mm3) at comparable time points during the study	<b>188</b>
Table .١٨	Morning cyclosporine A (CsA) dose (mg) at comparable time points during the study	<b>189</b>
Table .١٩	Night cyclosporine A (CsA) dose (mg) at comparable time points during the study	<b>190</b>
Table .٢٠	Mean blood cyclosporine A (CsA) trough level (ng / ml) at comparable time points during the study	<b>191</b>
Table .٢١	Total daily Tacrolimus dose (mg) at comparable time points during the study	<b>192</b>
Table .٢٢	Mean serum Tacrolimus level (ng / ml) at comparable time points during the study	<b>193</b>
Table .٢٣	Total daily Sirolimus dose (mg) at comparable time points during the study	<b>194</b>
Table .٢٤	Total daily Mycophenolate Mofetil (MMF) dose (gm) at comparable time points during the study	<b>195</b>
Table .٢٥	Total daily Azathioprine (mg) dose at comparable time points during the study	<b>196</b>
Table .٢٦	Total daily Corticosteroid dose (mg) at comparable time points	<b>197</b>

	during the study	
Table .٢٧	Comparison of induction therapy among the two studied groups	<b>198</b>
Table .٢٨	Medical Complications Post transplantation	<b>199</b>
Table .٢٩	Viral infection	<b>200</b>
Table .٣٠	Comparison of rejection in the two groups.	<b>201</b>
Table .٣١	State of graft at last follows up.	<b>202</b>
Table .٣٢	State of patient at last follow up	<b>203</b>
Table .٣٣	HCV effect on Medical Complications Post transplantation.	<b>203</b>
Table .٣٤	Comparison of HCV effect on rejection in the two groups.	<b>204</b>
Table .٣٥	Comparison of HCV effect on patient and graft survival.	<b>204</b>
Table .٣٦	Comparison of eGFR using Modification of Diet in Renal Disease (MDRD) formula among the two studied groups	<b>205</b>
Table .٣٧	Comparison of Duration (months) of anti tuberculosis drugs use among patients between the two groups	<b>206</b>
Table .٣٨	Comparison of No. of transplantation regimens among the two studied groups	<b>206</b>
Table .٣٩	Comparison of No. of switched regimens among the two studied groups	<b>208</b>
Table .٤٠	Comparison of the incidence of different liver complications among recipients in the hepatic group.	<b>209</b>

## Figures

Figure No	Title	Page
Figure .١	Comparison of the etiology of renal failure among the two groups	<b>181</b>
Figure .٢	Mean serum alanine transferase level ALT ( IU/liter) at comparable time points during study	<b>182</b>
Figure .٣	Mean serum Aspartate transaminase level AST(IU/liter) at comparable time points during study	<b>183</b>
Figure .٤	Mean serum bilirubin level (IU/liter) at comparable time points during study	<b>184</b>
Figure .٥	Mean serum albumin levels (g / dl) at comparable time points during study	<b>185</b>
Figure .٦	Mean hemoglobin values (gm /dl) at comparable time points during the study	<b>186</b>
Figure .٧	Mean blood WBCs values ( $10^3$ / $\text{mm}^3$ ) at comparable time points during the study	<b>187</b>
Figure .٨	Mean blood platelets values ( $10^3$ / $\text{mm}^3$ ) at comparable time points during the study.	<b>188</b>
Figure .٩	Morning cyclosporine A (CsA) dose (mg) at comparable time points during the study	<b>189</b>
Figure .١٠	Night cyclosporine A(CsA) dose (mg) at comparable time points during the study :	<b>190</b>
Figure .١١	Mean serum cyclosporine A (CsA) level (ng / ml) at comparable time points during the study	<b>191</b>
Figure .١٢	Total daily Tacrolimus dose (mg) at comparable time points during the study	<b>192</b>
Figure .١٣	Mean serum Tacrolimus level (ng / ml)	<b>193</b>

Figure	at comparable time points during the study	
Figure ١٤	Total daily Sirolimus dose at comparable time points during the study	<b>194</b>
Figure ١٥	Total daily Mycophenolate Mofetil (MMF) dose at comparable time points during the study	<b>195</b>
Figure ١٦	Total daily Azathioprine dose at comparable time points during the study	<b>196</b>
Figure ١٧	Total daily Corticosteroids dose at comparable time points during the study	<b>197</b>
Figure ١٨	Comparison of induction therapy among the two studied groups	<b>198</b>
Figure ١٩	Comparison of Medical Complications Post transplantation	<b>199</b>
Figure ٢٠	Comparison of Viral infection.	<b>200</b>
Figure ٢١	Comparison of rejection in the two groups.	<b>201</b>
Figure ٢٢	Comparison of No. of transplantation regimens among the two studied groups	<b>207</b>
Figure ٢٣	Comparison of the incidence of different liver complications among recipients in the hepatic group pre and post transplantation	<b>210</b>

## **Introduction**

Renal transplantation has become the treatment of choice for most patients with end-stage renal disease. Marked improvements in early graft survival and long-term graft function have translated into kidney transplantation being a more cost-effective alternative to dialysis (**Bradley, 2010**).

Liver disease has emerged as an important cause of morbidity and mortality in renal transplant recipients. Liver insufficiency is the cause of death in up to 28% of long-term survivors after renal transplantation (**Gheith et al, 2007**).

Elevation of the levels of the hepatic transaminases associated with discrete alterations in hepatic function is common post transplant and is usually a transient and self-limiting manifestation of drug toxicity. More severe manifestations of liver disease may require further investigation and modification of the immunosuppressive regimen (**William et al, 2005**).

Viral infection is an important cause of hepatic complications Post transplantation (**Ojo et al, 1998**).

Hepatitis C virus (HCV) infection is currently the major cause of chronic liver disease following kidney transplantation. The presence of HCV infection has been found to negatively affect the morbidity and mortality rates in patients on dialysis, in spite of that, it seems that kidney transplantation is a reasonable treatment option after a careful pretransplant evaluation (**Einollahi , 2010**).

Alanine transferase is a good marker of histologic hepatic lesion in HCV-infected Renal Transplant patients and, therefore, liver biopsy can be avoided in patients with persistently normal Alanine transferase (**Perez et al, 2005**).

HCV (Hepatitis C virus) infected transplant recipients with abnormal liver function have inferior survival rates. HCV infection in renal transplants is associated with greater rates of proteinuria and Chronic allograft nephropathy (**Mahmoud et al, 2004**).

HBV (Hepatitis B virus) related liver complications can present as de novo infection, acute flare in patients with chronic infection, chronic hepatitis, cirrhosis, or

hepatocellular carcinoma. The adverse impact of HBV infection on clinical outcomes has been reported by different investigators (**Tak Mao Chan ,2010**).

HBV infection decreased patient survival earlier than HCV and that HCV decreased graft survival more significantly than HBV. Both HBV and HCV were associated with rapid progression of chronic allograft nephropathy. HBV was the strongest risk factor for mortality compared with HCV, acute rejection episode, diabetes mellitus, or other hazardous factors (**Ingsathit , et al, 2007**).

Renal transplant patients infected concomitantly with HBV and HCV present a significantly lower long-term patient survival (**Corrêa et al, 2003**).

Herpes simplex viral hepatitis should be considered in immunocompromised persons with elevated serum transaminases without evidence of fulminant hepatic necrosis (**Duckro et al, 2006**).

Infection due to cytomegalovirus (CMV) is the most frequent opportunistic infection following renal transplantation. It is usually asymptomatic.

Cytomegalovirus disease causes fever, leucopenia, thrombocytopenia and slightly elevated transaminases (**Pérez-Valentín et al, 2002**).

Hepatotoxicity induced by immunosuppressants is difficult to evaluate since these drugs are sometimes used to treat liver diseases, or in combination with other drugs that can also cause hepatotoxicity. In addition, immunosuppressant therapy can favor the development of infections, which by themselves can cause liver damage, or reactivate latent chronic viral hepatitis (**Toscano et al, 2010**).

In a study using regimen of immunosuppression in renal transplantation composed of cyclosporine or (tacrolimus), mycophenolate, and steroid immunosuppression, in 50% of all patients serum alanine transferase (ALT) was elevated. There were more alanine transferase increases in patients on cyclosporine more than those who were on tacrolimus (**Kahu et al, 2005**).

Dose-dependent cyclosporine-induced hepatic dysfunction was observed early post-transplant. Neither tacrolimus- nor sirolimus-associated hepatic dysfunction was dose-dependent. Hepatic dysfunction had no significant impact

on either patient or graft survival; however, this finding may be due to the relatively short duration of follow up **(Gheith et al, 2007)**.

Azathioprine is a drug commonly used for the immunosuppression in renal transplantation. Hepatotoxicity is a rare, but important complication of this drug **(Romagnuolo et al, 1998)**.

Mycophenolate mofetil is a good alternative agent in special situations like acute/chronic liver diseases with elevated transaminases **(Srivastava et al, 2004)**.

Tuberculosis occurs at higher rates in renal transplant recipients than in the general population. It would be desirable to use isoniazid prophylaxis in renal transplant recipients at risk for reactivation of tuberculosis; yet many transplant centers do not routinely employ isoniazid prophylaxis because they perceive transplant recipients to be an enhanced risk of hepatotoxicity from isoniazid **(Antony et al, 1997)**.

The Model for End-Stage Liver Disease ( MELD )score is a numerical scale, ranging from 6 (less ill) to 40 (the most